On May 26, 2023, EF Hutton reaffirmed its coverage of Agenus (NASDAQ:AGEN), a clinical-stage immuno-oncology company. EF Hutton maintains its Buy recommendation for the company.
According to Fintel, the average one-year price target for Agenus as of May 11, 2023 is 7.73. This represents an increase of 432.86% from its closing price of 1.45. The range of forecasts is from a low of 6.06 to a high of $8.72.
The projected annual revenue for Agenus is 93MM, which is a 1.79% decrease. The projected annual non-GAAP EPS is -0.73.
A total of 304 funds or institutions reported positions in Agenus, which is a decrease of 3 owner(s) or 0.98% in the last quarter. The average portfolio weight of all funds dedicated to AGEN is 0.07%, a decrease of 23.95%. Total shares owned by institutions increased in the last three months by 14.02% to 215,805K shares. The put/call ratio of AGEN is 0.05, indicating a bullish outlook.
Some of the largest shareholders of Agenus are Deep Track Capital, XBI – SPDR(R) S&P(R) Biotech ETF, Artal Group, and Citadel Advisors.
Agenus is a Lexington, MA-based company focused on discovering and developing immuno-oncology therapies that engage the body’s immune system to fight cancer. The Company aims to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.